{"id":188866,"date":"2025-11-09T03:00:34","date_gmt":"2025-11-09T03:00:34","guid":{"rendered":"https:\/\/dailytalks.org\/?p=188866"},"modified":"2025-11-09T03:00:34","modified_gmt":"2025-11-09T03:00:34","slug":"ferrer-completes-recruitment-of-220-patients-for-the-prosper-study-a-phase-ii-clinical-trial-in-progressive-supranuclear-palsy-psp-two-months-ahead-of-schedule","status":"publish","type":"post","link":"https:\/\/dailytalks.org\/?p=188866","title":{"rendered":"Ferrer Completes Recruitment of 220 Patients for the PROSPER Study, a Phase II Clinical Trial in Progressive Supranuclear Palsy (PSP), Two Months Ahead of Schedule"},"content":{"rendered":"<p>This is a randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy, safety, and pharmacokinetics of FNP-223 (oral formulation) in slowing the progression of progressive supranuclear palsy (PSP) The study is being conducted across 44 centers in the European Union, the United Kingdom&#8230;<br \/><a href=\"https:\/\/financialpost.com\/pmn\/business-wire-news-releases-pmn\/ferrer-completes-recruitment-of-220-patients-for-the-prosper-study-a-phase-ii-clinical-trial-in-progressive-supranuclear-palsy-psp-two-months-ahead-of-schedule\" class=\"button purchase\" rel=\"nofollow noopener\" target=\"_blank\">Read More<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>This is a randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy,<\/p>\n","protected":false},"author":1,"featured_media":188867,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[16],"tags":[],"class_list":["post-188866","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-europe"],"featured_image_urls":{"full":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/11\/188866-ferrer-completes-recruitment-of-220-patients-for-the-prosper-study-a-phase-ii-clinical-tri691003d46f6b7.jpg",1000,750,false],"thumbnail":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/11\/188866-ferrer-completes-recruitment-of-220-patients-for-the-prosper-study-a-phase-ii-clinical-tri691003d46f6b7-150x150.jpg",150,150,true],"medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/11\/188866-ferrer-completes-recruitment-of-220-patients-for-the-prosper-study-a-phase-ii-clinical-tri691003d46f6b7-300x225.jpg",300,225,true],"medium_large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/11\/188866-ferrer-completes-recruitment-of-220-patients-for-the-prosper-study-a-phase-ii-clinical-tri691003d46f6b7-768x576.jpg",640,480,true],"large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/11\/188866-ferrer-completes-recruitment-of-220-patients-for-the-prosper-study-a-phase-ii-clinical-tri691003d46f6b7.jpg",640,480,false],"1536x1536":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/11\/188866-ferrer-completes-recruitment-of-220-patients-for-the-prosper-study-a-phase-ii-clinical-tri691003d46f6b7.jpg",1000,750,false],"2048x2048":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/11\/188866-ferrer-completes-recruitment-of-220-patients-for-the-prosper-study-a-phase-ii-clinical-tri691003d46f6b7.jpg",1000,750,false],"chromenews-featured":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/11\/188866-ferrer-completes-recruitment-of-220-patients-for-the-prosper-study-a-phase-ii-clinical-tri691003d46f6b7.jpg",1000,750,false],"chromenews-large":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/11\/188866-ferrer-completes-recruitment-of-220-patients-for-the-prosper-study-a-phase-ii-clinical-tri691003d46f6b7-825x575.jpg",825,575,true],"chromenews-medium":["https:\/\/dailytalks.org\/wp-content\/uploads\/2025\/11\/188866-ferrer-completes-recruitment-of-220-patients-for-the-prosper-study-a-phase-ii-clinical-tri691003d46f6b7-590x410.jpg",590,410,true]},"author_info":{"display_name":"Jonathan Jeriah","author_link":"https:\/\/dailytalks.org\/?author=1"},"category_info":"<a href=\"https:\/\/dailytalks.org\/?cat=16\" rel=\"category\">Europe<\/a>","tag_info":"Europe","comment_count":"0","_links":{"self":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/188866","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=188866"}],"version-history":[{"count":0,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/posts\/188866\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=\/wp\/v2\/media\/188867"}],"wp:attachment":[{"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=188866"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=188866"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/dailytalks.org\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=188866"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}